- Home
- ADSE vs TYRA Comparison
ADSE vs TYRA Comparison
Compare ADSE & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- TYRA
- Stock Information
- Founded
- ADSE 1980
- TYRA 2018
- Country
- ADSE Ireland
- TYRA United States
- Employees
- ADSE N/A
- TYRA N/A
- Industry
- ADSE Industrial Specialties
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- TYRA Health Care
- Exchange
- ADSE Nasdaq
- TYRA Nasdaq
- Market Cap
- ADSE 713.5M
- TYRA 576.6M
- IPO Year
- ADSE N/A
- TYRA 2021
- Fundamental
- Price
- ADSE $13.80
- TYRA $9.35
- Analyst Decision
- ADSE
- TYRA Strong Buy
- Analyst Count
- ADSE 0
- TYRA 7
- Target Price
- ADSE N/A
- TYRA $30.86
- AVG Volume (30 Days)
- ADSE 87.0K
- TYRA 419.0K
- Earning Date
- ADSE 05-12-2025
- TYRA 08-06-2025
- Dividend Yield
- ADSE N/A
- TYRA N/A
- EPS Growth
- ADSE N/A
- TYRA N/A
- EPS
- ADSE N/A
- TYRA N/A
- Revenue
- ADSE $113,896,884.00
- TYRA N/A
- Revenue This Year
- ADSE $219.58
- TYRA N/A
- Revenue Next Year
- ADSE N/A
- TYRA N/A
- P/E Ratio
- ADSE N/A
- TYRA N/A
- Revenue Growth
- ADSE 2.45
- TYRA N/A
- 52 Week Low
- ADSE $9.00
- TYRA $6.42
- 52 Week High
- ADSE $16.35
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ADSE 65.86
- TYRA 50.07
- Support Level
- ADSE $12.45
- TYRA $9.34
- Resistance Level
- ADSE $13.60
- TYRA $10.05
- Average True Range (ATR)
- ADSE 0.88
- TYRA 0.72
- MACD
- ADSE 0.30
- TYRA -0.05
- Stochastic Oscillator
- ADSE 97.54
- TYRA 28.15
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.